Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli

• Published in: Journal of cellular physiology Vol. 227; no. 4; pp. 1319 - 1325
• Main Authors: Fernando, Joan, Sancho, Patricia, Fernández-Rodriguez, Conrado M., Lledó, José L., Caja, Laia, Campbell, Jean S., Fausto, Nelson, Fabregat, Isabel
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2012; Wiley
• Subjects: Angiogenesis Inhibitors - pharmacology; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Apoptosis - physiology; Apoptosis Regulatory Proteins - antagonists & inhibitors; Apoptosis Regulatory Proteins - genetics; Apoptosis Regulatory Proteins - physiology; Autocrine Communication - drug effects; Autocrine Communication - physiology; Benzenesulfonates - pharmacology; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - physiopathology; Cell death; Cell Line, Tumor; Cell Proliferation - drug effects; Càncer de fetge; Gene Knockdown Techniques; Humans; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Liver Neoplasms - physiopathology; Mort cel·lular; Niacinamide - analogs & derivatives; Phenylurea Compounds; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - physiology; Pyridines - pharmacology; Signal Transduction - drug effects; Signal Transduction - physiology; Transforming Growth Factor beta - pharmacology; Tumor Necrosis Factor-alpha - pharmacology

Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC). The mechanism underlying this effect is not completely understood. In this work we have analyzed the effects of sorafenib on autocrine proliferation and survival of different human HCC cell lines. Our results...